Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV Type 1?

Clinical Infectious Diseases

Volumn 48, Issue 9, 2009, Pages 1310-1317

  Galli, Luisa ^a   Puliti, Donella ^b   Chiappini, Elena ^a   Gabiano, Clara ^c   Ferraris, Gabriele ^d   Mignone, Federica ^c   Viganò, Alessandra ^e   Giaquinto, Carlo ^g   Genovese, Orazio ^h   Anzidei, Gianfranco ⁱ   Badolato, Raffaele ^k   Buffolano, Wilma ^l   Maccabruni, Anna ^m   Salvini, Filippo ^f   Cellini, Monica ⁿ   Ruggeri, Maurizio ^o   Manzionna, Mariano ^p   Bernardi, Stefania ^j   Tovo, Pierangelo ^c   De Benedictis, F ^q   Osimani, P ^q   La Rovere, D ^q   Quercia, M ^q   Ruggeri, M ^q   Baldi, F ^q   Ciccia, M ^q   Faldella, A ^q   Masi, M ^q   Plebani, A ^q,q   Spinelli, E ^q   Dedoni, M ^q   Gariel, D ^q   Chiarello, P ^q   Magnolia, M G ^q   Sticca, M ^q   Vivalda, L ^q   Bezzi, T ^q   Fiumana, E ^q   Bianchi, L ^q   Battiglia, N ^q   Gervaso, P ^q   Bondi, E ^q   Cosso, D ^q   Gotta, C ^q   Ginocchio, L ^q   Rosso, R ^q   Viscoli, C ^q   Amoretti, C ^q   Esposito, S ^q   Farina, F ^q   Giacomet, V ^q   Lipreri, R ^q   Salvatici, E ^q   Stucchi, S ^q   Palazzi, G ^q   Paolucci, P ^q   De Luca, G ^q   Giannattasio, A ^q   Tancredi, F ^q   Tarallo, L ^q   Rampon, O ^q   Dalle Nogare, E ^q   Romano, A ^q   Saitta, M ^q   Mariani, B ^q   Biver, P ^q   Consolini, R ^q   Palla, G ^q   De Fanti, A ^q   Dodi, I ^q   Verna, M ^q   Bove, G ^q   Casadei, A M ^q   Castelli Gattinara, G ^q   Catania, S ^q   Martino, A M ^q   Sirufo, M M ^q   Ganau, A ^q   Cristiano, L ^q   Scolfaro, C ^q   Versace, A ^q   Portelli, V ^q   Gentilini, L ^q   Mazza, A ^q   Bernardon, M ^q   Bua, J ^q   Rabusin, M ^q   Pellegatta, A ^q   Fortunati, P ^q   de Martino, Maurizio ^a   more..

^a UNIVERSITY OF FLORENCE   (Italy)

^b Research Institute of the Tuscany Region   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Mangiagalli Hospital   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

ⁱ Gastroenterology and Hepatology   (Italy)

^j BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^k UNIVERSITY OF BRESCIA   (Italy)

^l UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^m UNIVERSITY OF PAVIA   (Italy)

ⁿ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^o Hospital of Bergamo   (Italy)

^p UNIVERSITY OF BARI   (Italy)

^q NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; ENFUVIRTIDE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CESAREAN SECTION; COHORT ANALYSIS; ENVIRONMENTAL EXPOSURE; FEMALE; FIRST TRIMESTER PREGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEWBORN; OUTCOME ASSESSMENT; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; THIRD TRIMESTER PREGNANCY; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; DELIVERY; DISEASE TRANSMISSION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; PREGNANCY COMPLICATION; RISK FACTOR; TREATMENT WITHDRAWAL;

ANTI-HIV AGENTS; COHORT STUDIES; DELIVERY, OBSTETRIC; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 65549086562     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597774     Document Type: Article

References (19)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction ofmaternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
2. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340:977-87.
3. The Italian Register for Human Immunodeficiency Virus Infection in Children. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch Pediatr Adolesc Med; 2002; 156:915-21.
4. Mandelbrot L, Landreau A, Rekacevicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV- 1. JAMA 2001;285:2083-93.
5. Cooper ER, Charurat M, Mofenson LM, et al. Combination antiret- roviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-94.
6. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458-65.
7. Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV- infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 8 July 2008:1-98. Available at: http://aidsinfo.nih. gov/ContentFiles/PerinatalGL.pdf. Accessed 9 March 2009.
8. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 January 1989-31 July 2005. Wilmington, NC: Registry Coordinating Center, 2005. Available at: http://www.APRegistry.com. Accessed 9 March 2009.
9. Galli L, Puliti D, Chiappini E, et al.; the Italian Register for HIV Infection in Children. Lower mother-to-child HIV-1 transmission in boys is independent of type of delivery and antiretroviral prophylaxis. J Acquir Immune Defic Syndr 2005; 40:479-85.
10. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. 1994. Available at: http://www.cdc/mmwr/preview/mmwrhtml/ 00032890.htm. Accessed March 20, 2009.
11. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000;284:190-7.
12. Bucceri AM, Somigliana E, Matrone R, et al. Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count. Am J Obstet Gynecol 2003; 189:545-51.
13. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
14. Garcia PM, Kalish LA, Pitt J, et al.; the Women and Infants Transmission Study Group. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. New Engl J Med 1999;341:394-402.
15. European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13:1377-85.
16. Duran AS, Losso MH, Salomon H, et al. Drug resistance among HIV- infected pregnant women receiving antiretrovirals for prophylaxis. AIDS 2007;21:199-205.
17. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-47.
18. European Collaborative Study. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007;44:1647-56.
19. Dunn DT, Brandt CD, Krivine A, et al. The sensitivity ofHIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intrauterine and intrapartum transmission. AIDS 1995; 9:F7-11.